Objective. To develop a model to predict buprenorphine plasma concentrations during transition from transdermal to buccal administration.
Introduction
Buprenorphine is a potent, semisynthetic opioid used to manage pain and treat opioid dependence [1] . The analgesic effect of buprenorphine is believed to be mediated primarily by way of partial agonist activity at the l-opioid receptor in vitro [2, 3] , whereas high-affinity antagonist action at the j-opioid receptor [2] may confer additional psychopathologic benefits [4, 5] . Partial agonist l-receptor pharmacology frequently conveys an expectation of weak efficacy, yet buprenorphine produces therapeutic analgesic effects at least as great as those of morphine, fentanyl, sufentanil, and oxycodone [6] and has an improved safety profile relative to other potent lopioid full agonists [7] .
Buprenorphine is available in multiple dosage forms [1] , including BUTRANS (buprenorphine) transdermal system (BTDS; Purdue Pharma LP, Stamford, CT, USA) and BELBUCA (buprenorphine) buccal film (BBF; Endo Pharmaceuticals Inc., Malvern, PA, USA), which are currently approved by the US Food and Drug Administration (FDA) for the management of pain severe enough to require daily, around-the-clock, long-term administration [8, 9] . Both formulations have demonstrated efficacy in managing pain in opioid-naïve and opioidexperienced patients [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .
In the United States, BTDS is available in doses of 5, 7.5, 10, 15, and 20 mcg/h [8] . Each patch is intended to be worn for seven days. Steady-state buprenorphine concentrations are achieved within 72 hours of application and decrease approximately 50% within 12 hours (range ¼ 10-24 hours) following system removal, with an apparent terminal half-life of approximately 26 hours [8, 22] . Relative to intravenous (IV) administration, the absolute bioavailability of BTDS is approximately 15% [8, 22] . In the United States, the BTDS patch is intended for use in patients requiring a morphine sulfate equivalent (MSE) dose of up to 80 mg/d, as the highest BTDS dose available (20 mcg/h) may not provide adequate analgesia in patients already receiving higher-dose opioid treatment (>80 mg MSE/d) [8] .
BBF is available in seven dose strengths (75, 150, 300, 450, 600, 750, and 900 mcg) [9] . The buccal film adheres to the inside of the cheek and fully dissolves without any remaining residual material, usually within 30 minutes. For most patients, BBF is administered twice daily. Following multiple-dose administration (60-240 mcg every [q] 12 hours), steady-state buprenorphine plasma concentrations are typically achieved prior to the sixth dose (72 hours, 3 days); thus, the recommended titration interval is four days [9, 23] . The mean plasma elimination half-life of buprenorphine is 27.6 hours [9] . Because buccal absorption bypasses first-pass metabolism, the absolute bioavailability of BBF is in the range of 46% to 65% [9, 23] . BBF is intended for use in patients requiring an MSE of up to 160 mg/d [9] , and therefore may be a viable option for patients who are already established on BTDS but whose therapeutic needs exceed its dosing capability, or for patients who experience side effects attributable to the BTDS dosage form (e.g., application site reactions).
Currently, no published data are available to guide clinicians who wish to convert patients from BTDS to BBF. The objective of the current analysis was to develop conversion scenarios for switching from BTDS to BBF using pharmacokinetic meta-modeling and simulation to understand the dose and timing parameters required to maintain consistent effective exposure that would result in minimal disruption to pain management without compromising patient safety.
Methods
A model-based meta-analysis of available published pharmacokinetic data was performed to develop a model that could describe both transdermal and buccal dosing and thereafter explore potential conversion scenarios. No clinical studies were conducted to investigate the conversion of a transdermal patch product to a buccal film formulation.
Systematic Search
Publications were identified through a PubMed Search using search terms "buprenorphine," "transdermal," "intravenous," "buccal," "pharmacokinetic," "modeling," and "NONMEM." Articles were selected for inclusion if they contained figures or tables of mean or median concentration time profiles, involved institutional review board (IRB)-approved studies that evaluated at least five participants per treatment, collected at least six pharmacokinetic observations, were peer-reviewed prior to publication, and were published in established journals (either clinical pharmacology journals or medical journals).
Data Extraction
Pharmacokinetic data (mean concentration vs time data) were extracted from eligible publications, and the time course of mean buprenorphine plasma concentrations achieved following application of a transdermal patch, buccal film, or IV (multiple dose levels for each product) was digitized using UN-SCAN-IT software (Silk Scientific Inc, Orem, UT, USA).
Model Development
Models were developed progressively: IV kinetics alone (assumed to represent systemic kinetics for all routes of administration); transdermal alone; buccal alone; IV and transdermal simultaneously; and IV, transdermal, and buccal simultaneously. The models were coded as differential equations in NONMEM and solved using the ADVAN13 subroutine (TOL ¼ 6). The random effects were at the study level (hence, estimating interstudy variability). Estimation of parameters was by the First Order Conditional Estimation (FOCE) method with eta-epsilon interaction. Parameter standard errors (SE%) were determined using Importance Sampling (IMP), which investigates the change in objective function value (OFV) around random samples of parameter values centered on the final parameter value. Conditional weighted residuals (CWRES) were used for model diagnostics.
Interstudy variability was represented as log-normal distribution for all random effect parameters. Intrastudy variability was represented by a proportional residual error model weighted by the inverse of the square root of the number of patients (NSUB) within each study:
where EPS is normally distributed (variance sigma), F is the individual model prediction, and Y is the model prediction with added error.
Models were ranked on the basis of goodness of fit as judged by changes in the minimum OFV. Models with poorly estimated parameter precision (e.g., SE > 50%) were considered to be potentially overparameterized, and consideration was given to simplifying the model.
Conversion Scenarios
The final model developed in NONMEM was transferred to the R language (www.r-project.org) for simulations. In this case, the model was written as differential equations and solved using the R package deSolve [24] . Predictions were based on population parameters (no representation of between-study variability). The average buprenorphine concentration for a dose interval was also plotted at the median time of the dose interval to better show the trend in concentration. The model was presented as an interactive web application to facilitate scenario testing [25] . Transition from a BTDS product to BBF was simulated using the web application for a variety of doses and dose intervals.
Results

Data Sources
The search yielded 10 potentially relevant publications, of which four were excluded for the following reasons: three studies had an incorrect patient population (pediatric population) and one study used the wrong formulation. Therefore, data from six studies were included in the meta-analysis (Table 1) [22, 23, [26] [27] [28] [29] ; these included three studies with IV buprenorphine, four studies with BTDS (two studies with comparators [IV buprenorphine and transdermal fentanyl]; two studies each with buprenorphine patch and Norspan patch [Mundipharma Pty Ltd, Sydney, AU-an identical transdermal formulation marketed in Australia, Canada, and other countries]) [30] , and one study with BBF (comparator IV buprenorphine).
Meta-Model Development
A meta-model could be developed that was a satisfactory description of the data extracted from the six studies ( Figure 1 ). IV buprenorphine pharmacokinetics were described using a three-compartment model with interstudy variability on clearance (CL), central volume of distribution (V1), peripheral volume of distribution (V2), and V1-V2 equilibrium (Q2). The tested models of transdermal absorption included: zero-order absorption, firstorder absorption, mixed zero and first-order absorption, time-dependent zero-order absorption, and transit compartments (N ¼ 0, 1, 2) between the patch and absorption site. The final transdermal absorption model ( Figure 2 ) used a zero-order rate constant that was modified by several factors. First, the rate was scaled by the nominal patch delivery rate (referenced to 5 mcg/h) [8] . Second, the rate was modified to reflect the time after patch application, with the absorption rate decreasing once the patch had been applied for several days (sigmoid function, defined by the time to half-loss and a slope [Hill] parameter). Third, the rate constant became zero when the patch was removed. The delivery rate at time zero was estimated to be dependent on the type of transdermal patch and was adjusted with a covariate. The delivery rate was approximately 43% slower for the Norspan patch compared with the BUTRANS patch. Buccal absorption was represented as a simple firstorder input with an absorption lag and bioavailability term. The final model parameters are shown in Table 2 .
Conversion Scenarios
The final model was used to simulate transition from a BTDS product to BBF. Simulations were produced for BTDS 10 mcg/h and 20 mcg/h every 168 hours for a total of four doses (Figure 3 ). After the fourth transdermal dose, buccal delivery commenced. For the 10-mcg/h BTDS, the buccal doses were 75 mcg after 12 hours, then 75 mcg q12h for four days, followed by additional upward titration to 150 mcg q12h for four days, then 300 mcg q12h for four days ( Figure 3A ). For the 20-mcg/h BTDS, the buccal doses were 150 mcg after 12 hours, then 150 mcg q12h for four days, followed by additional upward titration to 300 mcg q12h for four days, then 450 mcg q12h for four days ( Figure 3B ). In all cases, the switch to BBF was modeled to start 12 hours after removal of the BTDS product and included simulations predicting the buprenorphine plasma levels after up-titrating through three BBF dose strengths using an intertitration interval of four days between dose increments, consistent with recommendations in the BBF package insert [9] . For the 10-mcg/h BTDS, the model predicted that the conversion to 75-mcg BBF was likely to be inadequate, to 150-mcg BBF was likely to be approximately equivalent, and to 300-mcg BBF was likely to be supra-baseline. Similarly, for a 20-mcg/h BTDS, the model predicted the conversion to 150-mcg BBF was likely to be inadequate, to 300-mcg BBF was likely to be approximately equivalent, and to 450-mcg BBF was likely to be supra-baseline.
Discussion
Using data from the published literature, a three-compartment meta-model for IV, transdermal, and buccal buprenorphine pharmacokinetics was developed. The final transdermal model employed a zero-order input rate that was influenced by patch delivery rate and time after application of the patch (with a decline in rate over time). The transdermal absorption rate constant became zero when the patch was removed. Transdermal fentanyl has previously been described using a first-order absorption process [31, 32] . This model was not a good description of the present data set and was not considered to be compatible with the design characteristics of the transdermal patches (zero-order release). A "stochastic" transdermal absorption rate constant has also been used to describe transdermal buprenorphine [33] , which also allowed the absorption rate to vary with time. The approach used here, where the patch delivered at a zero-order rate that began to decrease after approximately two days, was able to describe the available data and was considered mechanistically plausible. Our meta-model data predict that transdermal patch formulations will be unable to maintain a constant delivery over seven days, and this is consistent with data provided in the BUTRANS label [8] , which further illustrates a substantial ($50%) decline in plasma buprenorphine concentration from days 2 to 7 when dosing with 10-mcg/h BTDS. Potential explanations for the inability to sustain steady-state plasma exposures are obscure but are not likely to be due to depletion of the drug reserve within the patch; a 10-mcg/h BTDS, for example, contains 10 mg of buprenorphine within the patch matrix [34] , and simple arithmetic suggests that only 1.68 mg of the drug load will be dispensed over a seven-day wear period, with $80% of the drug therefore discarded at the point of patch removal. The absorption model was dose-proportional, and the kinetics of buprenorphine were linear; these parameters also hold true for the BBF formulation [23] .
Two BTDS-to-BBF conversion scenarios were considered for simulation using the developed meta-model (10-mcg/h or 20-mcg/h BTDS to BBF). For both, a relatively rapid and straightforward approach to conversion to BBF was used. A 12-hour interval between patch removal and initiation of buccal therapy was selected based on the model-predicted decline in plasma levels following patch removal ($40% decrease in the 12 hours after the point of patch removal, corresponding to an $55% decrease from maximum plasma concentration [C max ] at day 2 of patch application). The illustrated BBF starting doses (75 mcg and 150 mcg, respectively) were conservative with respect to predicted C max excursions relative to prior BTDS steady-state plasma buprenorphine. Subsequent dose titration (75-to 150-mcg dose increments, consistent with recommendations described in the BBF package insert [9] ) produced average plasma concentrations that were higher than those with transdermal administration by the third dose level (300 mcg q12h and 450 mcg q12h, respectively). Figure 2 Buprenorphine transdermal model. Intravenous buprenorphine pharmacokinetics were described using a three-compartment model with between-participant variability on clearance (CL), central volume of distribution (V1), peripheral volume of distribution (V2), and V1-V2 equilibrium (Q2).
These simulations illustrate a potential avenue for buprenorphine dose escalation in patients currently managed with the BTDS formulation, but who appear to require higher doses of buprenorphine than are commercially available in the transdermal dosage form in the United States. Similarly, they may provide additional information for clinicians seeking to convert patients from transdermal to buccal administration due to issues of tolerability Figure 3 Simulated conversion of BTDS to BBF. (A) BTDS 10 mcg/h to BBF: BTDS 10 mcg/h q7d (168 h) for four weeks (to 672 hours), transition to BBF 75 mcg after 12 hours, then continue BBF 75 mcg q12h for four days (to 768 hours), followed by additional upward titration to BBF 150 mcg q12h for four days (to 864 hours), followed by a final up-titration to BBF 300 mcg q12h for four days (to 960 hours). (B) BTDS 20 mcg/h to BBF: BTDS 20 mcg/h q7d (168 hours) for four weeks (to 672 hours), transition to BBF 150 mcg after 12 hours, then continue BBF 150 mcg q12h for four days (to 768 hours), followed by additional upward titration to BBF 300 mcg q12h for four days (to 864 hours), followed by a final up-titration to BBF 450 mcg q12h for four days (to 960 hours). BBF ¼ buprenorphine buccal film; BTDS ¼ buprenorphine transdermal system; q ¼ every.
or other concerns. One such concern might be durability of effect with the BTDS formulations, given the appreciable decline in buprenorphine plasma levels by the time a patch is replaced at day 7 [8] .
It is important to stress that the modeling and simulations described in this study do not represent clinical experience, and thus must be interpreted accordingly. All of the published studies included in this analysis were conducted in healthy volunteers, and thus did not evaluate pharmacokinetics in individuals with chronic pain (the target population) or in those with other potential confounding issues such as hepatic impairment or the concomitant administration of other central nervous system depressants or cytochrome P450 3A4 activityenhancing or -inhibiting drug therapies [22, 23, [26] [27] [28] [29] . These simulations are intended only as information for clinicians to consider when assessing how to convert a patient from BTDS to BBF. Final judgment as to starting BBF dose and titration parameters rests with the prescribing physician, and close monitoring during the transition period is recommended. Signs of under-or overdosing should be managed accordingly.
Conclusions
Computer simulations of BTDS-to-BBF conversion using a pharmacokinetic meta-model suggest that a relatively rapid and straightforward conversion from BTDS to BBF is feasible. Additionally, this modeling further illustrates the wide range of BBF doses available to achieve plasma buprenorphine exposures above those possible with the maximum BTDS strength for those patients who require higher doses to achieve adequate pain relief.
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